FDA advisors are resigning because of Biogen's Alzheimer's drug approval
The drug was approved, but when supporters were interviewed they couldn't say anything more compelling than that they were receiving the news positively because people suffered from Alzheimer's, without being able to say anything in favor of the drug itself.
The drug came out a while back, and was not approved upon review last year (because no benefits were substantially proven, the FDA advisory board voted 10 against, 1 uncertain, 0 in favor), and since then nothing has changed, but the FDA decided to approve it now.
It is rare for this type of decision to be overturned, and usually when it does happen, it's after a vote that is closer than the Biogen drug was.
There are millions of potential consumers for the drug, and Biogen has priced it at $56,000 per year.
Commenters said that after the third resignation, there might be some real attention on what's going on here.
3 prestigious FDA advisors who quit: